The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback